Selecting initial therapy in chronic lymphocyt... - CLL Support
Selecting initial therapy in chronic lymphocytic leukemia - ASH 2022 Education Program
You need to be a member of this community to see this post.
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over...
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
February 2020
A long paper and too much information to be able to summarise in this post but a nice...
New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors
MS-553 is a protein kinase C-beta (PKCß) inhibitor designed to be an alternative treatment option...
ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista
Prof Nicole Lamanna - ASH 2019 - Maturing CLL clinical trial data
Dr. Nicole Lamanna, Associate...
Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
3rd April 2020 Blood
Key points to note:
BTK inhibitor therapy achieves durable disease...
New Dana Farber Research 
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
A new kid on the block? Nemtabrutinib
CLL responses to Pfizer’s Covid vaccines. 
